Search clinical trials for: 2nd line therapy

Total 59052 results

Chinese PLA General Hospital

Recruiting

CAPOX + Bevacizumab + Tirelizumab Treating PDL1 CPS < 5 GEA

Advanced Gastroesophageal Adenocarcinoma | First-line Therapy | PDL1 CPS < 5

China
Hellenic Society of Hematology
Sanofi

Not yet recruiting

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood Protein Disorders | Renal Impairment

Greece
Andrew E. Place, MD
University of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaborators

Recruiting

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditions

United States
Qianfoshan Hospital

Recruiting

Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion

Non Small Cell Lung Cancer

China
Yonsei University

Not yet recruiting

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

HER2-positive Gastric Cancer

Korea, Republic of
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade

Esophageal Squamous Cell Carcinoma
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Dokuz Eylul University
The Scientific and Technological Research Council of Turkey

Recruiting

Online Group Therapy for Breast Cancer

Breast Cancer

Turkey
Fudan University
Zhejiang Provincial People's Hospital

Not yet recruiting

A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer

Advanced Pancreatic Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
The Central Hospital of Lishui City

Not yet recruiting

TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma
Liaoning Tumor Hospital & Institute
Huludao central hospital; Anshan Tumor Hospital; Chaoyang Central Hospital; Fukuang...

Not yet recruiting

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Breast Neoplasm Female
NYU Langone Health

Recruiting

Assessing the Effects of Patient Self-Rating of Voice Quality on Voice Therapy Attendance and Outcomes

Dysphonia

United States
Fudan University

Recruiting

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Metastatic Colorectal Cancer

China
Asahi Kasei Pharma Corporation

Recruiting

Value of Glycated Albumin in Intervention of Glycemic Control in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

China
Leiden University Medical Center

Recruiting

Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy (TAILOR)

Autoimmune Hepatitis

Netherlands
Masaryk University
Masaryk Memorial Cancer Institute

Recruiting

Effectiveness and Suitability of the Online Mobile Application for the Mental and Physical Health of Cancer Patients

Cancer

Czechia
Qingdao Central Hospital

Recruiting

Anlotinib Plus PD-1 Inhibitor as 2nd-line Threapy in Patients With Metastatic Pancreatic Cancer

Overall Survival

China
Fudan University
Chongqing University Cancer Hospital; Sun Yat-sen University; Peking University... and other collaborators

Recruiting

Immune Therapy in HR-positive/HER2-negative Metastatic Breast Cancer(ENIGMA)-BCTOP-L-M02

Breast Cancer | Metastatic Cancer

China
Viriom

Not yet recruiting

Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2NRTIs From the 1st Line Standard of Care Therapy

HIV-1-infection

Russian Federation
Medical University of Silesia

Recruiting

Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy

Graves Orbitopathy

Poland
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
First Affiliated Hospital Bengbu Medical College

Recruiting

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

Triple-negative Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

HER2-positive Breast Cancer | Adjuvant Therapy

China
Dennis M. McNamara, MD, MS
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy (REBIRTH)

Peripartum Cardiomyopathy, Postpartum

United States
Mental Health Services in the Capital Region, Denmark
Region of Southern Denmark; Copenhagen Trial Unit, Center for Clinical Intervention... and other collaborators

Recruiting

TEENS Multi-site Trial

Self-Injurious Behavior

Denmark
Sixth Affiliated Hospital, Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.; Nanjing Geneseeq Technology Inc.

Recruiting

Study on the Biomarker of First-line Immunotherapy Combined With Chemotherapy in Advanced Esophageal Cancer

Advanced Esophageal Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Colorectal Cancer Stage IV

China
Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; Massachusetts General Hospital; University of Missouri-Columbia and other collaborators

Recruiting

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes (BESTMED)

Diabetes Mellitus, Type 2

United States
Wuhan Union Hospital, China

Recruiting

Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC

Colorectal Neoplasms Malignant

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting

Ovarian Neoplasms
Medtronic Cardiovascular

Recruiting

Evolut™ EXPAND TAVR II Pivotal Trial

Moderate Aortic Valve Stenosis

United States, France, Netherlands, Canada, Spain, Israel, Australia, Denmark, Germany, Italy, Japan, Switzerland, Belgium, Sweden, Austria, United Kingdom, Ireland
Institute of Hematology & Blood Diseases Hospital

Recruiting

PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma

Refractory Hodgkin Lymphoma | Relapse | Hodgkin Lymphoma, Adult

China
Peking Union Medical College Hospital

Not yet recruiting

Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

Thrombotic Thrombocytopenic Purpura, Acquired

China
Hellenic Cooperative Oncology Group

Recruiting

Osimertinib as 1st Line Therapy for Patients With Advanced EGFR Positive Non-Small Cell Lung Cancer

Lung Cancer Non-small Cell Stage IV

Greece
Centre for Addiction and Mental Health
Breaking Free Online (BFO); Community Addictions Peer Support Association (CAPSA)

Recruiting

Online Cognitive Behavioural Therapy for Substance Use Disorder: The Impact of Peer Support

Substance Use Disorders

Canada
Dr. Nazanin Alavi
Online PsychoTherapy Clinic

Recruiting

Investigating the Effectiveness of e-CBTi Compared to Pharmaceutical Interventions in Treating Insomnia

Insomnia

Canada
SonALAsense, Inc.

Recruiting

A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients With DIPG

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma

United States
National Cancer Institute (NCI)

Recruiting

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Glioblastoma | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Astrocytoma, Not Otherwise Specified | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Glioblastoma, Not Otherwise Specified

United States, Australia, New Zealand, Canada
Fudan University

Recruiting

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

Gastric Cancer | Metastasis

China
UMC Utrecht
Dutch Colorectal Cancer Group

Recruiting

Radioembolization in Elderly/ Fragile Patients With mCRC (CAIRO7)

Colorectal Cancer Metastatic

Netherlands
Sheba Medical Center
Bristol-Myers Squibb

Recruiting

Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer

Stage IV Pancreatic Cancer

Israel
Universidad Nacional Autonoma de Mexico

Not yet recruiting

Online Transdiagnostic Intervention for Emotional Disorders and Stress-related Disorders

Depression | Anxiety Disorders | Emotional Disorder | Stress Related Disorder

Mexico
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Stereotactic Biopsy Split-Course Radiation Therapy in Diffuse Midline Glioma, SPORT-DMG Study

Diffuse Midline Glioma, H3 K27M-Mutant

United States
Intergroupe Francophone du Myelome
Bristol-Myers Squibb; Sanofi

Recruiting

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy (IsAMYP)

AL Amyloidosis

France
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
Assistance Publique - Hôpitaux de Paris
Société de Dermatologie Française

Not yet recruiting

Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence (NAKIMEL)

Melanoma
Fudan University

Recruiting

Cryoablation Combined With Tislelizumab Plus Lenvatinib as Second-line or Later Therapy in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score

Prostate Adenocarcinoma

United States, Canada
Peking Union Medical College Hospital

Recruiting

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma | PD-1 Inhibitor | Regorafenib

China

Search clinical trials for: 2nd line therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations